PubMed Health⌕ Search

PubMed · 12085568

[Intestines and joints: an entity?].

Abstract

The intestinal inflammation and the inflammatory arthropathy in Crohn's disease and in spondyloarthropathy are tightly linked. Both forms of inflammation occur in clinical and subclinical forms in both diseases: 60% of patients with Crohn's disease have clinical and/or radiological signs of articular involvement--65% of patients belonging to the concept of spondyloarthropathy have endoscopic and/or histological signs of gut inflammation. The macrophages and the lymphocytes play a role either by the transport of bacterial antigens by macrophages from the gut to the synovium, either by the recirculation of activated lymphocytes attracted to the tissue by adhesion molecules. In both diseases, TNF alpha play a central role resulting in a rapid and spectacular improvement of the intestinal and articular inflammation by the administration of a monoclonal chimeric antibody directed against this cytokine (Infliximab). This clinical effect is associated or secondary to a restoration of the production of proinflammatory cytokines. According the importance of genetic factors in the etiopathogenesis of both diseases (mutation in the NOD2 gene for Crohn--HLA-B27 phenotype for spondyloarthropathy) future studies are necessary to find a common alteration explaining the link between gut and joint. This knowledge can help in the elucidation of the origin of both diseases.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M De Vos. 2002. [Intestines and joints: an entity?].. https://pubmed.ncbi.nlm.nih.gov/12085568/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

ZrO₂@C-based colorimetric/photothermal dual-mode immunosensor coupled with a novel monoclonal antibody for quantification of Aspergillus ochraceus biomass.

Aspergillus ochraceus contaminates agricultural products and produces nephrotoxic, carcinogenic ochratoxin A (OTA), posing severe food safety hazards. A dual-signal lateral flow immunochromatographic assay (dLFIA) based on ZrO₂@C nanoprobes was established for quantitative detection of A. ochraceus biomass. A novel monoclonal antibody (mAb 4B4) was prepared as the capture antibody to immobilize A. ochraceus mycelial lysate antigen on the test line, and a rabbit polyclonal antibody (pAb G2801) as the detection antibody to modify ZrO₂@C composites (synthesized via UiO-66 pyrolysis) into 200 nm colorimetric/photothermal nanoprobes. This dLFIA achieved limits of detection of 0.164 μg/mL (colorimetric) and 0.517 μg/mL (photothermal). This efficient and reliable method allows quantitative analysis of A. ochraceus biomass, which is suitable for routine monitoring of fungal contamination in agro-food matrices.

Antibodies, Monoclonal↗

Rituximab for lymphoproliferative disease prior to haematopoietic stem cell transplantation for X-linked severe combined immunodeficiency.

Lymphoproliferative disease (LPD) is a complication of congenital and acquired immunodeficiency states. There are a number of treatment options for LPD arising after haematopoietic stem cell or solid organ transplantation including reduction of immunosuppression, targeted therapies, such as the anti-CD20 monoclonal antibody, rituximab, and EBV specific cytotoxic lymphocytes. Treatment of LPD in children with congenital immunodeficiency syndromes remains unsatisfactory and is associated with a high mortality rate. We recently managed an infant found to have polymorphic LPD concurrent with X-linked severe combined immunodeficiency (SCID). Haematopoietic stem cell transplantation (HSCT) had to be deferred because of progressive LPD. Treatment with rituximab resulted in regression of the LPD following which the patient received a 5/6 HLA matched umbilical cord blood (UCB) transplant. The patient remains well 20 months following transplantation. Rituximab treatment may have a useful role in the control of LPD associated with congenital immunodeficiency prior to HSCT.

Antibodies, Monoclonal↗

Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus.

Opsoclonus-myoclonus (OM) is a paraneoplastic syndrome of probable autoimmune origin. Despite current therapies aimed at decreasing autoantibody formation, OM is difficult to control and may impact long-term neurologic outcome. We present a case of a 19-month-old patient who initially presented with OM, neuroblastoma and a constitutional cytogenetic abnormality t(5;12)(q11.2;q15). The patient's OM was recalcitrant to conventional therapies, but showed significant improvement following treatment with rituximab.

Antibodies, Monoclonal↗